Colony-stimulating factor-1 suppresses responses to CpG DNA and expression of toll-like receptor 9 but enhances responses to lipopolysaccharide in murine macrophages

被引:85
作者
Sweet, MJ [1 ]
Campbell, CC
Sester, DP
Xu, DM
McDonald, RC
Stacey, KJ
Hume, DA
Liew, FY
机构
[1] Univ Queensland, Inst Mol Biosci, Brisbane, Qld 4072, Australia
[2] Univ Queensland, Dept Biochem, Brisbane, Qld 4072, Australia
[3] Univ Glasgow, Dept Bacteriol & Immunol, Glasgow, Lanark, Scotland
关键词
D O I
10.4049/jimmunol.168.1.392
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
During bacterial infections, the balance between resolution of infection and development of sepsis is dependent upon the macrophage response to bacterial products. We show that priming of murine bone marrow-derived macrophages (BMMs) with CSF-1 differentially regulates the response to two such stimuli, LPS and immunostimulatory (CpG) DNA. CSF-1 pretreatment enhanced IL-6, IL-12, and TNF-alpha production in response to LPS but suppressed the same response to CpG DNA. CSF-1 also regulated cytokine gene expression in response to CpG DNA and LPS; CpG DNA-induced IL-12 p40, IL-12 p35, and TNF-alpha mRNAs were all suppressed by CSF-1 pretreatment. CSF-1 pretreatment enhanced LPS-induced IL-12 p40 mRNA but not TNF-alpha and IL-12 p35 mRNAs, suggesting that part of the priming effect is posttranscriptional. CSF-1 pretreatment also suppressed CpG DNA-induced nuclear translocation of NF-kappaB and phosphorylation of the mitogen-activated protein kinases p38 and extracellular signal-related kinases-1/2 in BMMs, indicating that early events in CpG DNA signaling were regulated by CSF-1. Expression of Toll-like receptor (TLR)9, which is necessary for responses to CpG DNA, was markedly suppressed by CSF-1 in both BMMs and thioglycolate-elicited peritoneal macrophages. CSF-1 also down-regulated expression of TLR1, TLR2, and TLR6, but not the LPS receptor, TLR4, or TLR5. Hence, CSF-1 may regulate host responses to pathogens through modulation of TLR expression. Furthermore, these results suggest that CSF-1 and CSF-1R antagonists may enhance the efficacy of CpG DNA in vivo.
引用
收藏
页码:392 / 399
页数:8
相关论文
共 41 条
[11]  
Cowdery J, 1996, J IMMUNOL, V156, P4570
[12]   SYNERGISTIC INTERACTION OF BACTERIAL LIPOPOLYSACCHARIDE AND THE MONOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR - POTENTIAL QUANTITATIVE AND QUALITATIVE CHANGES IN MACROPHAGE-PRODUCED CYTOKINE BIOACTIVITY [J].
EVANS, R ;
KAMDAR, SJ ;
DUFFY, TM ;
FULLER, J .
JOURNAL OF LEUKOCYTE BIOLOGY, 1992, 51 (01) :93-96
[13]   CSF-1 regulation of Il6 gene expression by murine macrophages:: a pivotal role for GM-CSF [J].
Evens, R ;
Shultz, LD ;
Dranoff, G ;
Fuller, JA ;
Kamdar, SJ .
JOURNAL OF LEUKOCYTE BIOLOGY, 1998, 64 (06) :810-816
[14]   Persistent activation of mitogen-activated protein kinases p42 and p44 and ets-2 phosphorylation in response to colony-stimulating Factor 1/c-fms Signaling [J].
Fowles, LF ;
Martin, ML ;
Nelsen, L ;
Stacey, KJ ;
Redd, D ;
Clark, YM ;
Nagamine, Y ;
McMahon, M ;
Hume, DA ;
Ostrowski, MC .
MOLECULAR AND CELLULAR BIOLOGY, 1998, 18 (09) :5148-5156
[15]  
FRENDL G, 1990, J IMMUNOL, V144, P3400
[16]   MECHANISMS OF ENDOTOXIN-SHOCK AND ENDOTOXIN HYPERSENSITIVITY [J].
GALANOS, C ;
FREUDENBERG, MA .
IMMUNOBIOLOGY, 1993, 187 (3-5) :346-356
[17]   Immune cell activation by bacterial CpG-DNA through myeloid differentiation marker 88 and tumor necrosis factor receptor-associated factor (TRAF)6 [J].
Häcker, H ;
Vabulas, RM ;
Takeuchi, O ;
Hoshino, K ;
Akira, S ;
Wagner, H .
JOURNAL OF EXPERIMENTAL MEDICINE, 2000, 192 (04) :595-600
[18]   CpG-DNA-specific activation of antigen-presenting cells requires stress kinase activity and is preceded by non-specific endocytosis and endosomal maturation [J].
Häcker, H ;
Mischak, H ;
Miethke, T ;
Liptay, S ;
Schmid, R ;
Sparwasser, T ;
Heeg, K ;
Lipford, GB ;
Wagner, H .
EMBO JOURNAL, 1998, 17 (21) :6230-6240
[19]   A MAP KINASE TARGETED BY ENDOTOXIN AND HYPEROSMOLARITY IN MAMMALIAN-CELLS [J].
HAN, J ;
LEE, JD ;
BIBBS, L ;
ULEVITCH, RJ .
SCIENCE, 1994, 265 (5173) :808-811
[20]  
HAPEL AJ, 1985, J IMMUNOL, V134, P2492